{"disease":{"id":"atopic-hypersensitivity","name":"atopic hypersensitivity"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03627767","title":"Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1235,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03720470","title":"Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":838,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT07316465","title":"Birth Cohort: Development of IgE Autoantibodies in Newborns With (High Risk of) Atopic Dermatitis","phase":"NA","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Universitair Ziekenhuis Brussel","has_results":false},{"nct_id":"NCT05003804","title":"Allergic Disease Onset Prevention Study","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":283,"lead_sponsor_name":"Siolta Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03054428","title":"Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":251,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT03563066","title":"Effect of Benralizumab in Atopic Dermatitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"McMaster University","has_results":true}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}